[{"orgOrder":0,"company":"Neurasic Therapeutic","sponsor":"McGill University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Acid-sensing ion channel","graph1":"Neurology","graph2":"Discovery","graph3":"Neurasic Therapeutic","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurasic Therapeutic \/ McGill University","highestDevelopmentStatusID":"2","companyTruncated":"Neurasic Therapeutic \/ McGill University"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Discovery","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The project included rational design of novel candidates, in-silico 3D docking studies on the 5HT2A serotonin receptor, and screening of the candidates in an in-vitro platform, to assess the receptor activation.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 19, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Data showing precision selectivity for neurotoxic TDP-43 and alpha-synuclein publishes in Neurology.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          September 04, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Neurasic’s potential drug therapy targets acid-sensing ion channels (ASICs), a gene family of neuronal receptors activated by protons that play a role in multiple neurological disorders.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 06, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : McGill University

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank